Form 8-K - Current report:
SEC Accession No. 0001558370-22-015319
Filing Date
2022-10-25
Accepted
2022-10-25 16:01:39
Documents
15
Period of Report
2022-10-25
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K tmb-20221025x8k.htm   iXBRL 8-K 35267
2 EX-99.1 tmb-20221025xex99d1.htm EX-99.1 40544
3 GRAPHIC tmb-20221025xex99d1001.jpg GRAPHIC 14345
  Complete submission text file 0001558370-22-015319.txt   234881

Data Files

Seq Description Document Type Size
4 EX-101.SCH tmb-20221025.xsd EX-101.SCH 3808
5 EX-101.DEF tmb-20221025_def.xml EX-101.DEF 3496
6 EX-101.LAB tmb-20221025_lab.xml EX-101.LAB 17260
7 EX-101.PRE tmb-20221025_pre.xml EX-101.PRE 10063
9 EXTRACTED XBRL INSTANCE DOCUMENT tmb-20221025x8k_htm.xml XML 4889
Mailing Address 29 EMMONS DRIVE SUITE B-10 PRINCETON NJ 08540
Business Address 29 EMMONS DRIVE SUITE B-10 PRINCETON NJ 08540 609-538-8200
SOLIGENIX, INC. (Filer) CIK: 0000812796 (see all company filings)

EIN.: 411505029 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-14778 | Film No.: 221329507
SIC: 2834 Pharmaceutical Preparations